Our findings shed new light on the therapeutic potential of targeting the circNOX4/miR-329-5p/FAP/IL-6 axis to reprogram CAFs into a quiescent state and improve clinical outcomes in NSCLC patients. Here, IL6 is linked to non-small cell lung carcinoma.